InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
08 août 2024 07h30 HE
|
InflaRx N.V.
Hosted research and development (R&D) event focused on the differentiation of INF904 and its potential in addressing significant unmet needs in inflammation & immunology (I&I)Initiation of...
InflaRx to Report Second Quarter 2024 Results on August 8, 2024
01 août 2024 07h30 HE
|
InflaRx N.V.
JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases
30 juil. 2024 07h30 HE
|
InflaRx N.V.
JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced...
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
24 juin 2024 08h02 HE
|
InflaRx N.V.
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced...
InflaRx Hosts R&D Event Highlighting the Promise of INF904
05 juin 2024 12h00 HE
|
InflaRx N.V.
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential...
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
21 mai 2024 14h30 HE
|
InflaRx N.V.
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data...
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
08 mai 2024 07h30 HE
|
InflaRx N.V.
Virtual R&D event to be held on June 5, 2024 from 12:00 to 2:00 PM EDT – highlighting company plans for INF904 and the opportunity, the role of C5aR in chronic spontaneous urticaria (CSU) and...
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
30 avr. 2024 07h30 HE
|
InflaRx N.V.
JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
24 avr. 2024 07h30 HE
|
InflaRx N.V.
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
21 mars 2024 07h00 HE
|
InflaRx N.V.
InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and potentially best-in-class oral C5aR inhibitor...